BG Medicine Q3 Revenues Up 56 Percent, But Potential Nasdaq De-listing Looms | GenomeWeb

BG Medicine this week reported third quarter revenues of $1 million, up 56 percent from $641,000 in the third quarter of 2012.

The revenue increase was driven by $1 million in sales of the company's BGM Galectin-3 test, a 64 percent jump from the $610,000 it posted in Q3 2012. BG also reported $23,000 in revenues from its services business, down 26 percent from $31,000 a year ago.

The company's revenues matched the average Wall Street estimate of $1 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions. is eyeing an expansion into genomic risk assessments, the Verge reports.